Tamro Group sales rise 20%
This article was originally published in Clinica
Sales at the hospital and laboratory division of Finnish company Tamro rose 17% in the first four months of 1996 to FMk 162 million ($34 million). Operating profit in this sector was FMk 21 million, compared with FMk 18 million in 1995. The company says a strike in the healthcare sector in 1995 reduced sales by around FMk 10 million.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.